Bacterin Announces Updates on Executive Leadership Transition Plans

  Bacterin Announces Updates on Executive Leadership Transition Plans

Company in final stages of identifying search firm; several candidates express
                                   interest

Business Wire

BELGRADE, Mont. -- April 17, 2013

Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the
development of revolutionary bone graft material and coatings for medical
applications, today announced that it is in the final stages of identifying a
key executive search firm to assist with the identification of a new Chief
Executive Officer. The Company has narrowed its selection to three search
firms and noted that it expects to have selected a firm by the end of next
week.

“It is business as usual here at Bacterin,” said Kent Swanson, Chairman of
Bacterin International. "We have been pleased with the speed at which our
board and management team – headed by interim Co-CEO’s, John Gandolfo, Chief
Financial Officer, and Darrel Holmes, Chief Operating Officer – have
diligently worked to align and stabilize the business as the result of our
recent management transition and to retain a search firm for our new Chief
Executive Officer position. Our business remains stable and our employees are
now more optimistic about the prospects of the Company.”

The Company also announced solid progress with cost reduction measures
designed to generate positive EBITDA.

Mr. Swanson further commented, “I am confident of the value proposition our
products and services offers to the market place. The candidate for our Chief
Executive Officer position will have an understanding of our product portfolio
and will have a track record of developing markets in this evolving healthcare
environment. This candidate will represent a new vision and era of growth and
progress for Bacterin International.”

About Bacterin International Holdings

Bacterin International Holdings, Inc. (NYSE MKT: BONE) develops, manufactures
and markets biologics products to domestic and international markets.
Bacterin's proprietary methods optimize the growth factors in human allografts
to create the ideal stem cell scaffold to promote bone, subchondral repair and
dermal growth. These products are used in a variety of applications including
enhancing fusion in spine surgery, relief of back pain, promotion of bone
growth in foot and ankle surgery, promotion of cranial healing following
neurosurgery and subchondral repair in knee and other joint surgeries.

Bacterin's Medical Device division develops, employs, and licenses coatings
for various medical device applications. For further information, please visit
www.bacterin.com.

Important Cautions Regarding Forward-looking Statements

This news release contains certain disclosures that may be deemed
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 that are subject to significant risks and
uncertainties. Forward-looking statements include statements that are
predictive in nature, that depend upon or refer to future events or
conditions, or that include words such as "continue," "efforts," "expects,"
"anticipates," "intends," "plans," "believes," "estimates," "projects,"
"forecasts," "strategy," "will," "goal," "target," "prospects," "potential,"
"optimistic," "confident," "likely," "probable" or similar expressions or the
negative thereof. Statements of historical fact also may be deemed to be
forward-looking statements. We caution that these statements by their nature
involve risks and uncertainties, and actual results may differ materially
depending on a variety of important factors, including, among others: the
Company's ability to launch beta and full product releases; the Company's
ability to meet its obligations under existing and anticipated contractual
obligations; the Company's ability to develop, market, sell and distribute
desirable applications, products and services and to protect its intellectual
property; the ability of the Company's sales force to achieve expected
results; the ability of the Company's customers to pay and the timeliness of
such payments, particularly during recessionary periods; the Company's ability
to obtain financing as and when needed; changes in consumer demands and
preferences; the Company's ability to attract and retain management and
employees with appropriate skills and expertise; the impact of changes in
market, legal and regulatory conditions and in the applicable business
environment, including actions of competitors; and other factors. Additional
risk factors are listed in the Company's Annual Report on Form 10-K under the
heading "Risk Factors." The Company undertakes no obligation to release
publicly any revisions to any forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events, except as required by law.

Contact:

COCKRELL GROUP
Rich Cockrell, 877-889-1972
investorrelations@thecockrellgroup.com
cockrellgroup.com